Roivant Sciences Ltd.
ROIVNASDAQHealthcare● Active
$28.49
$-0.09(-0.31%)
Market Cap$20.5B
P/E Ratio—
52W High$32.793
52W Low$10.705
Roivant Sciences Ltd. (ROIV) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ROIV · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($397.91M) | ($356.73M) | $4231.21M | ($1115.46M) | ($924.12M) |
| Depreciation & Amort. | $3.35M | $14.07M | $22.04M | $18.86M | $5.93M |
| Stock-Based Comp. | $346.17M | $289.03M | $199.63M | $217.78M | $564.96M |
| Change in Working Capital | ($621.80M) | ($77.05M) | $19.04M | $6.34M | $15.72M |
| Net Cash from Operations | ($750.35M) | ($839.45M) | ($765.27M) | ($843.39M) | ($677.73M) |
| Investing Activities | |||||
| Capital Expenditure | ($8.21M) | ($4.60M) | ($1.38M) | ($12.69M) | ($17.44M) |
| Purchases of Investments | $0.00M | ($4061.52M) | $0.00M | $0.00M | $0.00M |
| Sales of Investments | ($37.49M) | $1960.00M | $0.00M | $0.00M | $320.17M |
| Net Cash from Investing | ($682.33M) | ($1766.29M) | $5203.62M | ($44.27M) | $303.30M |
| Financing Activities | |||||
| Common Stock Repurchased | ($319.50M) | ($1293.23M) | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | ($6.00M) | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | ($52.75M) | ($30.70M) | $129.75M | $14.81M |
| Net Cash from Financing | $134.24M | ($1219.79M) | $419.36M | $499.46M | $306.79M |
| Free Cash Flow | |||||
| Free Cash Flow | ($758.56M) | ($844.05M) | ($766.65M) | ($856.08M) | ($695.16M) |
| FCF Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Roivant Sciences Ltd. data
About Roivant Sciences Ltd. (ROIV) Cash Flow Statement
Roivant Sciences Ltd. generated operating cash flow of ($0.75B) and free cash flow of ($0.76B) for 2026 — a FCF margin of -9183.51%. Capital expenditure was ($0.01B).
Frequently asked questions
ROIV · 4 questionsRoivant Sciences Ltd. generated free cash flow of ($0.76B) for 2026, up 10.1% year-over-year.
ROIV free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10